

Attorney Docket No.: 6680.200-US
USSN: 10/822,020


REMARKS

The specification is amended to include material incorporated by reference in the application that was omitted from the specification due to a filing error. Specifically, Tables 3, which is also found in incorporated US Patent Application 60/467,079, was partially cut off in the filed application. Table 4 was included in its entirety in the filed specification, but is confusing in the specification as filed due to what is clearly a formatting error (data from one line is carried over to the following line unintentionally).

The present amendment to the specification provides a version of Table 3 that corresponds to the Incorporated material and that correct this inadvertent loss of data and a version of Table 4 that is less confusing. In view of the incorporation of Table 3 in the priority provisional application, and the formal nature of the changes to Table 4, no new matter is added by these amendments.

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Date: September 27, 2004

Len S. Smyth, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Please use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE